Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

Thursday, June 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The COMPASS 2.0 study evaluates the comparative effectiveness of nab-paclitaxel versus standard chemotherapy in patients with platinum-resistant ovarian cancer. Presented by Dr. Mark S. Shahin at the European Society for Medical Oncology Gynaecological Cancers Annual Congress, the findings contribute valuable insights into treatment options for this challenging patient population.
Price reaction · baseline $80.88 (2026-06-18T15:59:00.000Z) · hit during market hours · 2 other CORT headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study presents real-world data on treatment effectiveness.
  • Nab-paclitaxel is being compared to standard therapies.
  • The presentation is part of a reputable medical congress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
4.8%
average across 6 past catalysts
Lead asset
mifepristone+ fluvastatin
Phase 1 · Healthy Subjects

Full Press Release Details

Presented : European Society for Medical Oncology Gynaecological Cancers Annual Congress , 1 8 June 2026, Copenhagen , DK
Presenter : Mark S. Shahin , MD, FACOG, FACS
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0) appeared first on Corcept Therapeutics .

Frequently Asked Questions

What is the COMPASS 2.0 study about?

The COMPASS 2.0 study compares the effectiveness of nab-paclitaxel to standard chemotherapy in platinum-resistant ovarian cancer patients.

Who presented the COMPASS 2.0 findings?

Dr. Mark S. Shahin presented the findings at the European Society for Medical Oncology Gynaecological Cancers Annual Congress.

Where was the COMPASS 2.0 study presented?

The study was presented at the European Society for Medical Oncology Gynaecological Cancers Annual Congress in Copenhagen.

What type of cancer does the COMPASS 2.0 study focus on?

The study focuses on platinum-resistant ovarian cancer patients.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare nab-paclitaxel ovarian cancer platinum-resistant chemotherapy
Last updated: Jun 18, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
mifepristone+ fluvastatinPhase 1
Healthy Subjects →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →